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Abstract: Previously, we have reported the synthesis of a homochiral L-cyclic peptide
[WR]5 and its use for delivery of anti-HIV drugs and biomolecules. A physical mixture of
HAuCl4 and the peptide generated peptide-capped gold nanoparticles. Here, [WR]5 and
[WR]5-AuNPs were tested for their efficiency to deliver a small interfering RNA molecule
(siRNA) in human cervix adenocarcinoma (HeLa) cells. Flow cytometry investigation
revealed that the intracellular uptake of a fluorescence-labeled non-targeting siRNA
(200 nM) was enhanced in the presence of [WR]5 and [WR]5-AuNPs by 2- and 3.8-fold
when compared with that of siRNA alone after 24 h incubation. Comparative toxicity
results showed that [WR]5 and [WR]5-AuNPs were less toxic in cells compared to other
available carrier systems, such as Lipofectamine.
Keywords: small interfering RNA (siRNA) delivery; gold nanoparticles; cyclic peptides;
siRNA delivery systems (DDS)

1. Introduction
Small interfering RNA (siRNA) is a class of RNA molecules that elicits knockdown of its
complimentary target mRNA and consequently inhibits the expression of the corresponding protein [1].
siRNA has been extensively investigated as one of the relatively modern therapeutics in the treatment
of various diseases [2–7]. However, further clinical investigation of siRNA has been challenging due
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to their relatively large size, poor intracellular uptake due to the presence of negatively charged
phosphate groups in their structure, and enzymatic degradation under in vivo environment [8,9]. Thus,
several delivery systems, such as polymeric-based [10], cholesterol containing [11], lipid-based like
liposomes [12], and carbon nanotubes (CNTs) [13] have been employed to improve several properties
of siRNA including limited intracellular delivery, degradation in serum, and off-target effects.
Despite this development, siRNA-mediated delivery systems have not been entirely successful
since the majority of delivery systems exhibited significant cytotoxicity and showed limited potential
for siRNA delivery in some cell lines [14–18]. For instance, post-mitotic primary neuron cells showed
high resistance to lipofectamin [18]. Meanwhile, due to the great therapeutic potential of siRNA,
developing efficient delivery systems is highly demanded in clinical investigations. Currently,
Lipofectamine has been used as one of the common systems for siRNA delivery. However, in several
cases, like E18 rat embryonic cortical and hippocampal cells the transfection efficiency was significantly
low (3%–25%) [19].
In last two decades, cell-penetrating peptides (CPPs) have been widely employed as non-viral
intracellular carriers by taking advantage of their unparalleled properties like biocompatibility and cell
penetration ability to cross the plasma membrane or through endocytic pathways [20]. A wide range of
molecular cargos, such as small drugs [21–24], biologically important molecules [25], and relatively
large liposomes [26,27] have been transported by using CPP-mediated delivery methods. Structurally,
the majority of CPPs contain positively charged amino acids (e.g., arginine and/or lysine). The
presence of positive charge on the surface of CPPs helps them to interact with negatively charged
elements (e.g., heparin and/or phosphate groups) in cell membrane structure. This interaction can trigger
the internalization of the peptide.
In addition to the cell penetrating capability of CPPs, the molecular cargos loading and release are
significantly important in overall functionality of the system. Thus, to date, several CPPs have been
discovered that can be employed as transportation tools for the intracellular delivery of different
biomolecules through non-covalent interaction. Furthermore, loading molecular cargos through
non-covalent interactions offers significant advantages including smooth release of drug in their intact
form and simple loading procedure when compared with the covalent methods [28,29]. Technically,
amino acids with lipophilic regions like tryptophan can generate a hydrophobic region. The presence
of the hydrophobic region can further assist the system to entrap the relatively large biomolecules. The
formation of cargo complex-CPP through mostly electrostatic interaction and hydrophobic forces is a
simple and easy approach. The complex formation can reform the structure and induce cell permeability
to the conformation of relatively large molecules. Furthermore, positively charged portion of CPPs are
able to hold the negatively charged backbone in siRNAs structure. These nonspecific electrostatic
interactions facilitate the carrier-siRNA complex formation. In addition, other parameters like the molar
and/or charge ratio of the CPPs to siRNA can control the functionality of the system. It has been reported
that the excess amount of CPPs can facilitate the formation of the CPP-siRNA complex and cover the
surface of the complex by positive charge to increase the cell permeability of the system [30].
Moreover, the hydrophobic portion of the CPPs could be responsible for the entrapment of siRNA and
disturbs the stabilization of the plasma membrane. Recently, several in vivo investigations have
reported by employing the non-covalent approach between CPP and siRNA [31].
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During the last few years we have been investigating the application of cyclic peptides in the
delivery of a wide range of cargos (including anticancer agents, anti-HIV drugs, and negatively
charged phosphopeptides). The cyclic conformation of the peptide offers higher cell penetrating ability
and stability over linear counterparts. Our studies showed that the intracellular uptake of several
molecular cargos can be significantly enhanced in the presence of a cyclic peptide containing alternative
arginine and tryptophan namely [WR]5 [20,32,33]. Moreover, the formation of [WR]5-capped gold
nanoparticles were discovered to improve the intracellular delivery of model anti-HIV drugs and
phosphopeptides [34,35]. In continuation of our efforts to develop new applications of cyclic peptidebased drug delivery systems for transporting biomolecules, we report here the use of [WR]5- and
[WR]5-AuNPs for improving the cellular delivery of siRNA. To the best of our knowledge, this is the
first report of using cyclic peptide-based delivery systems for cellular transporting of siRNA.
2. Results and Discussion
2.1. Synthesis of the Cyclic Peptide
A cyclic decapeptide containing alternative L-arginine and L-tryptophan (Scheme 1) was
synthesized by using 9-fluorenylmethyloxycarbonyl (Fmoc)-based chemistry based on our previously
reported method [20,32,33]. The peptide was designed based on the presence of hydrophobic
tryptophan and positively charged arginine. The presence of positively charged arginine residues is
critical since they can trigger electrostatic interactions with negatively charged elements in the cell
membrane, such as phosphate groups and heparin residues. Furthermore, tryptophan helps to generate
a hydrophobic region and facilitate the transportation of siRNA through disturbing the phospholipid
bilayer and leads to a higher uptake. The combination of tryptophan and arginine residues induced the
reaction of the peptide with HAuCl4 solution. Mechanistically, tryptophan has been used for the
formation of gold nanoparticles since this amino acid can reduce Au3+ into Au°. Moreover, arginine
attracts the negatively charged charged aurate anions into the reaction site [24]. Thus, this mixure of
amino acids could be an optimized arrangement to increase the yield of gold nanoparticles synthesis,
and an efficient collection for cellular uptake enhancement (Scheme 2).
Scheme 1. Chemical structures of [WR]5 and [WR]5-AuNPs.
NH2

H2N

H 2N

NH2

H 2N

HO
N

O
NH HN
O
HN HN
OHN
HN
H 2N NH

NH

H2N

NH O

N
OH
HN

NH H N
2
NHO
N NH 2
H
NH
O
NH
O N
H
NH
O
HN NH 2
NH 2

NH

O

H2N

NH

NH
O
HN

O

HN
NH
HN

O
HN
H2N

HAuCl4 / H2O/ Room Temperature (4h)

NH2

N
H
O

HN

H2N

H 2N

H O
N

HN

NH

NH
O
HN

NH

NH
O

N
O H

O

HN

HN

N
H
NH2
NH2

NH2

NH
H O
N

NH
O

NH

HN
H2N

O
NH

H2N

NH2

N
H
O

O
NH
HN

O
HN
H2N

N
O H
HN

O

HN

H O
N

NH

NH2

N
H

NH
O

HN

NH
O HN

NH2

H2N

O

HN

N
H

NH2

NH
NH O

O
NH

HN

NH
HN

H2N
H2N

HN
O

HN

NH

O

HN

H2N

NH O
NH

NH

HN
H2N

NH2

2

[WR]5

NH2

H 2N

AuNPs

NH2

H2N

[WR]5-AuNPs

NH2

N
O H
HN

O

O N
H
HN

NH2
NH2

Molecules 2014, 19

13322
Scheme 2. Solid-phase synthesis of cyclic [WR]5.
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2.2. Synthesis of Peptide-Capped Gold Nanoparticles
The synthesis of [WR]5-AuNPs was performed by an in situ method. The peptide was dissolved in
water (1 mM) and mixed with an aqueous solution of HAuCl4 (1 mM). The peptide-capped
nanoparticles were obtained after 4 h incubation at room temperature. The final concentrations of gold
and peptides were adjusted to be 500 μM. The purple color showed the formation of CPP-AuNPs.
Mechanistically, the CPP works as reducing and capping agents to generate peptide capped AuNPs in
one step. The synthesized peptide-capped gold nanoparticles were characterized by different
techniques such as UV-Vis spectroscopy, transmission electron microscopy (TEM), and dynamic light
scattering (DLS) techniques as previously reported by us [35]. The formation of synthesized
nanoparticles was confirmed as their characteristic peak showed up at 540 nm (Figure S1). Scanning
electron microscopy (SEM) images showed that nanoparticles formed in a size range of 200–230 nm
(Figure S2). DLS also validated the size of nanoparticles. Furthermore, zeta potential was used to
measure the charge on the surface of nanoparticles. The elevation in zeta potential of [WR]5 and
[WR]5-AuNPs were determined to be +56.2 ± 7.6 mv and +18.35 ± 2.5 mv respectively. These data
showed that the positively charged arginine residues can cover the surface of nanoparticles through
electrostatic interactions.
2.3. Cytotoxicity of siRNA Delivery Systems
Initially, the peptide and the corresponding peptide capped-gold nanoparticles were tested for their
toxicity in human cervical adenocarcinoma (HeLa) cells. We compared the cytotoxicity of [WR]5 and
[WR]5-AuNPs CPPs with transfection reagents, such as polyarginine (CR7), TAT (YGRKKRRQRRRC),
and Lipofectamine (Lipo2000®, a cationic lipid formulation) at different incubation times (24–72 h).
As it is shown in Figure 1, [WR]5-AuNPs (25 μM) and [WR]5 (25 μM) exhibited significantly lower
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toxicity in HeLa cells compared to other CPPs like polyarginine (25 μM), TAT (25 μM), and
Lipofectamine (200 nM) by 21%–55%. Based on the cytotoxicity results, the noncytotoxic concentration
of 25 μM was chosen for further studies.
Figure 1. Cytotoxicity of the [WR]5 and corresponding peptide-capped AuNPs compared
to other siRNA delivery systems.
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2.4. Cellular Uptake of F′-siRNA by Flow Cytometry
To evaluate [WR]5-AuNPs and [WR]5 as siRNA transporters, a model experiment with non-targeting
fluorescent siRNA, F′-siRNA (where F′ = 5,6-carboxyfluorescein (FAM), GenePharma, Shanghai,
China) as a cargo molecule was performed. This siRNA with a sequence of 5'-UUC UCC GAA CGU
GUC ACG UTT-3' was selected as a model cargo to determine the efficiency of the system. Due to the
presence of the negatively charged segments in the structure of siRNA, an efficient cellular uptake is
critical for its activity. HeLa cells were incubated with F′-siRNA (200 nM) in the presence or absence
of transporters [WR]5-AuNPs and [WR]5 (25 μM) for 24 h at 37 °C and then treated with trypsin to
remove cell surface-bound siRNA. Intracellular uptake of F′-siRNA was measured in cells using
fluorescence activated cell sorter (FACS). FACS showed higher fluorescence signal in cells treated
with F′-siRNA-loaded [WR]5 and [WR]5-AuNPs compared to that of F′-siRNA alone. For instance, the
cellular uptake of F′-siRNA-loaded [WR]5-AuNPs and F′-siRNA-loaded [WR]5 were found to be
approximately 3.8- and 2-fold higher for F′-siRNA than those of F′-siRNA alone, respectively
(Figure 2), suggesting that the uptake of siRNA is facilitated by the carriers. These data also suggest
that a [WR]5 and their AuNPs can enhance cellular association of the siRNA. Peptide-capped gold
nanoparticles showed higher efficiency in delivering siRNA into cells compared to the peptide alone.
Both AuNPs and [WR]5 have been reported as cellular delivery agents. The combination of both in
peptide-capped AuNPs will generate nanoparticles with more transfection efficiency. AuNPs have
highly active surface for binding to siRNA. The formation of peptide-capped AuNPs changes the
orientation of amino acids in the structure of the peptide and enhances their efficiency.
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Figure 2. Cellular uptake of F′-siRNA in the presence and absence of [WR]5 and
[WR]5-AuNPs after 4 h incubation.
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2.5. Cellular Uptake of F′-siRNA by Microscopy
To confirm the improvement of cellular uptake of the siRNA, the fluorescence intensity of
F′-siRNA was visualized in HeLa cells by microscopy techniques. Microscopy results exhibited the
localization of F′-siRNA-loaded [WR]5-AuNPs and F′-siRNA-loaded [WR]5. Lipofectamine was used
as a control for microscopy studies. We found that the presence of Lipo2000® enhanced the
fluorescence signal in cells suggesting the intracellular uptake of the F′-siRNA. However, higher
intensity was observed in the presence of [WR]5-AuNPs compared to that of Lipo2000®, suggesting
that this lipid-based reagent did not work as efficiently as the peptide-capped AuNPs. These data
confirmed that the presence of the peptide and peptide-capped AuNPs are critical for the enhanced
cellular permeability of the molecular cargo (Figure 3).
2.6. Cellular Uptake of F'-[WR]5-AuNPs
Previously, the procedure for the synthesis of F′-[WR]5-AuNPs was reported by us [35]. The
mechanistic investigations showed that the uptake of F′-[WR]5-AuNPs by cells did not change when
endocytic inhibitors were used (Supporting Information, Figure S3). However, EIA had a minor effect
on the uptake suggesting that lipid-raft-dependent micropinocytosis and phagocytosis pathways could
be slightly responsible for transporting the drug across the cell membrane.
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Figure 3. Fluorescence microscope images of F′-siRNA uptake by HeLa cells in the presence
of [WR]5 and [WR]5-AuNPs after 4 h incubation. No green fluorescence was observed in
the presence of F′-siRNA alone. BF: Brightfield, FITC: Fluorescein isothiocyanate.
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3. Experimental Section
3.1. General Methods
All reagents were purchased from Wilkem Scientific (Pawtucket, RI, USA). Other chemicals and
reagents were purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI, USA). Coupling
reagents, trityl chloride resin, and Fmoc-amino acid building blocks were purchased from Chem-Impex
International Inc. (Wood Dale, IL, USA). The non-targeting fluorescent labeled siRNA (FAM-siRNA)
was purchased from GenePharma. The sequence osf the siRNA was 5'-UUC UCC GAA CGU GUC
ACG UTT-3'. The siRNA against FANCD2 was purchased from Ambion (Grand Island, NY, USA)
with a sense sequence of 5'-CAG CCA ACC UGA GAU CCU ATT-3', and antisense of 5′-UAG GAU
CUC AGG UAG GCU GGT-3'.
3.2. Synthesis of [WR]5
The cyclic peptide synthesis was performed by our previously reported procedure [32,33]. Bio-Rad
polypropylene columns were used as reaction vessels, and all reactions were carried out by shaking
and mixing in a Glass-Col small tube rotator under N2 gas at room temperature. For peptide synthesis,
solid-phase method employing N-(9-fluorenyl)methoxycarbonyl (Fmoc)-based chemistry and
Fmoc-L-amino acid building blocks were used. 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
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hexafluoro phosphate (HBTU) and N,N-diisopropylethylamine (DIPEA) were used for coupling
and activating amino acids respectively in N,N-dimethylformamide (DMF). Fmoc deprotection was
carried out by using piperidine in DMF (20% v/v). A mixture of trifluoroethanol (TFE)/acetic
acid/dichloromethane (DCM) (2:2:6, v/v/v, 15 mL) was used for cleaving the side chain protected
peptide from the resin for 2 h. The resin was filtered off, and the solvent was evaporated to collect the
linear peptide with side chain protecting groups. To synthesize the cyclic peptide from the linear one, a
mixture of 1-hydroxy-7-azabenzotriazole (HOAt, 163.3 mg, 1.2 mmol) and N,N′-diisopropylcarbodiimide
(DIC, 187.0 µL, 1.2 mmol) in dry DMF (100 mL) and dry DCM (40 mL) for 18 h was used. The
deprotection of peptide side chains was carried by using a mixture of trifluoroacetic acid
(TFA)/thioanisole/anisole/1,2-ethanedithiol (EDT) (90:5:2:3 v/v/v/v) for 2 h. Cold diethyl ether (Et2O)
was used to precipitate the peptide. The crude peptide was purified by reversed-phase Hitachi HPLC
(L-2455) on a Phenomenex Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm). The
peptide was purified by eluting the crude peptide at 10.0 mL/min using a gradient of 0%–100%
acetonitrile (0.1% TFA) and water (0.1% TFA) over 60 min. The peptide was then lyophilized. A
high-resolution Biosystems QStar Elite time-of-flight electrospray mass spectrometer and a MALDI
AXIMA Performance TOF/TOF mass spectrometer (Shimadzu, Tokyo, Japan) were employed to
confirm the chemical structure of [WR]5 as described previously [21,22]. Analytical HPLC was used
to confirm the purity of final products (>95%, Figure S4). The analytical HPLC was performed on
Thermo Hypersil Gold C18 analytical column (150 × 4.6 mm).
3.3. Spectral Data
[WR]5: HR-MS (ESI-TOF) (m/z): C85H110N30O10: calcd, 1710.9021; found, 1711.6974 [M+H]+,
571.5658 [M+3H]3+, 428.9286 [M+4H]4+, 343.1493 [M+5H]5+.
3.4. Synthesis of Peptide-Capped Gold Nanoparticles
The synthesis of AuNPs was carried out by using [WR]5 peptide and visual evaluation technique.
Mixing HAuCl4 (1 mM) and [WR]5 (1 mM) solutions led to the formation of peptide-capped AuNPs.
The cyclic peptide was dissolved in deionized water (1 mL) to prepare the stock solution (1 mM). The
stock solution (1 mL, 1 mM) was mixed with HAuCl4 solution (1 mL, 1 mM) to synthesize AuNPs.
The color of the solution was turned into purple upon the formation of AuNPs. Subsequently, all
concentrations in cell based assays was calculated based on the concentration of the peptide solution
and HAuCl4 solution.
3.5. Scanning Electron Microscopy (SEM)
To prepare a sample for SEM microscopy, [WR]5-AuNPs (5 μL of 0.5 mM solution in H2O)
solution was spotted onto a carbon-coated copper grid (300 mesh). The liquid drop was then allowed to
stay on the carbon film for 10 min. The excess of the solution was removed from the surface of the grid,
and the sample was kept overnight to get dried. SEM analyses of [WR]5-AuNPs were conducted in an
FEI Nova NanoSEM (Hillsboro, OR, USA) using the directional backscatter (DBS) electron detector.
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3.6. Cell Culture
Human cervix adenocarcinoma (HeLa) cells (ATCC no CCL-2) was obtained from the American
Type Culture Collection (Manassas, VA, USA). Cells were grown on 75 cm2 cell culture flasks with
EMEM medium, supplemented with 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin
solution (10,000 units of penicillin and 10 mg of streptomycin in 0.9% NaCl) in a humidified atmosphere
of 5% CO2, 95% air at 37 °C.
3.6.1. Cytotoxicity Assay
The cytotoxicity assay was performed through MTS cell viability assay. HeLa cells (4000) were
seeded in 0.1 mL per well in 96-well plates 24 h prior to the experiment. The old medium (EMEM
containing FBS (10%)) was changed by compounds including [WR]5 (25 μM), [WR]5-AuNPs
(25 μM), Lipofectamine (2 µg/mL), polyarginine (25 μM), and TAT peptide (25 μM) in serum
containing medium and incubated for 24–72 h at 37 °C in a humidified atmosphere of 5% CO2. 20 μL
of CellTiter 96 aqueous solution (Promega, Madison, WI, USA) was added. Cell viability was calculated
with the fluorescence intensity at 490 nm using a SpectraMax M2 microplate spectrophotometer. The
percentage of cell survival was calculated as [(OD value of cells treated with the test mixture of
compounds) − (OD value of culture medium)]/[(OD value of control cells) − (OD value of culture
medium)] × 100%.
3.6.2. Microscopy Imaging
HeLa cells were grown with antibiotic-free DMEM 24 h prior to the experiment in 6-well plates
(2 × 105 cells in 1 mL media per well). The FAM-siRNA was incubated with [WR]5, [WR]5-AuNPs, or
Lipofectamine for 30 min at room temperature. Then, the cells were treated with a mixture of
FAM-siRNA (200 nM) and [WR]5 (25 μM), [WR]5-AuNPs (25 μM), or Lipofectamine (2 μg/mL) in
Opti-MEM for 4 h and 24 h at 37 °C. After a specific incubation time, the media containing the
treatments was removed, and PBS was added to cells. Microscopy was carried out using a Zeiss Axio
Imager (Oberkochen, Germany) A1 and Vision Rel. 4.6, Dell Optiplex 735. The imaging was carried
out under fluorescence and bright field at 50×, 100×, and 400× magnifications. Images were merged
using Adobe Photoshop in order to visualize the localization of fluorescence.
3.6.3. Flow Cytometry
HeLa cells were taken in 6-well plates with the population of 3 × 105 cells per well in opti-MEM.
Then, the fluorescence-labelled siRNA (FAM-siRNA, F′-siRNA, 200 nM) alone and in combination
with [WR]5 (25 μM) and [WR]5-AuNPs (25 μM) were added to the different wells in serum with no
media. The plates were incubated for 4 h at 37 °C. As a negative control, wells with no treatment and
F′-siRNA alone were used. After 4 h incubation, the media containing the treatments were removed. The
cells were digested with 0.25% trypsin/ EDTA (0.53 mM) for 5 min to remove any artificial surface
binding. Then the cells were washed twice with PBS. Finally, the cells were resuspended in flow
cytometry buffer and analyzed by flow cytometry (FACSVerse flow cytometer, San Jose, CA, USA)
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using FITC channel and CellQuest software. The data presented were based on the mean fluorescence
signal for 10,000 cells collected. All assays were performed in duplicate.
3.6.4. Mechanism of Cellular Uptake when Endocytic Inhibitors Are Used
Cells were kept in 6-well plates prior to performing the assay. All wells containing cells were
incubated with endocytic inhibitors 30 min before the treatment. Several inhibitors like methyl-βcyclodextrin (2.5 mM), chloroquine (100 μM), nystatin (50 μg/mL), 5-(N-ethyl-N-isopropyl)amiloride
(EIA, 50 μM), and chlorpromazine (30 μM) were used. The media was removed and cells were
incubated with a combination of F′-[WR]5-AuNPs and inhibitors for 4 h. Similar FACS analysis
method was used to evaluate the data.
4. Conclusions
In conclusion, a new class of cyclic peptide and corresponding cyclic peptide-capped AuNPs
containing arginine and tryptophan were evaluated for the delivery of siRNA. They showed to be
efficient in the intracellular delivery of F′-siRNA. Furthermore, [WR]5-AuNPs showed negligible
toxicity up to 100 μM in HeLa cells. However, the concentration of 25 µM was used for cell-based
assays. [WR]5-AuNPs was able to function as a transporter of fluorescence-labeled siRNA and
intracellularly. The high cellular internalization of the labeled drugs by [WR]5-AuNPs suggests the
potential application of these nanoparticles as a molecular transporter. The present results provide
preliminary insights for further optimization in degradation, binding, and release properties of cyclic
peptide-based carriers in this class as siRNA delivery transporters.
Supplementary Materials
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/19/9/13319/s1.
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